SCHEMBL3020108

SCHEMBL3020108

CCCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4c(F)c(F)c(F)c(F)c4F)CC3)n2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.48
MAPK1 P28482 6/20 0.47
LMNA P02545 4/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 11/20 0.46
RAB9A P51151 6/20 0.46
NPC1 O15118 5/20 0.46
ALDH1A1 P00352 3/20 0.44
MAPT P10636 4/20 0.44
HTT P42858 2/20 0.44
AR P10275 2/20 0.42
TSHR P16473 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3009046 0.92 MAPK1 (0.49) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3021992 0.90 MAPK1 (0.47) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3009746 0.87 SMN1; SMN2 (0.56) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3007264 0.87 MAPK1 (0.41) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3008237 0.87 SMN1; SMN2 (0.58) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3014979 0.87 SMN1; SMN2 (0.47) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3020204 0.87 MAPK1 (0.45) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3014091 0.86 AOC3 (0.35) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL2998872 0.85 SMN1; SMN2 (0.48) L3MBTL1MAPK1LMNAMEN1KMT2A
SCHEMBL3012599 0.85 SMN1; SMN2 (0.54) L3MBTL1MAPK1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA L3MBTL1 1847/4885MAPK1 2767/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.